Business Wire

NV-VERACODE

1.8.2024 13:56:35 CEST | Business Wire | Press release

Share
As Developers Struggle to Prioritize Security Debt, Veracode Announces Latest Innovations to Identify and Unify Critical Risk

Black Hat USA Conference (booth #2536) – Veracode, a global leader in application risk management, today announced platform innovations to help organizations uncover, prioritize, and reduce security debt across their growing attack surface. Universal Connector and Application Security Heatmap, the two newest capabilities from Longbow powered by Veracode, allow organizations to quickly connect findings from any source and see the applications that are contributing to the most risk. Together, the Universal Connector and the Application Security Heatmap provide clear, operational insight into assets and issues, allowing remediation actions to be prioritized by quantifiable risk.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240801020287/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Figure 1: State of Software Security 2024 Language Snapshot (Graphic: Business Wire)

“The combination of mounting security debt, an expanding attack surface made more vulnerable by generative AI, and an overwhelming volume of security alerts makes it challenging for organizations to know which application risks to prioritize,” said Chris Eng, Chief Research Officer at Veracode. “In fact, our State of Software Security research shows that many organizations are more focused on remediating low-severity flaws than critical flaws. Security leaders need technology that enables them to effectively uncover and manage application risk, and then reduce that risk by focusing on the issues that matter most across their entire attack surface.”

Prioritization of Security Debt: Critical vs Non-critical

In its State of Software Security 2024 Language Snapshot, Veracode revealed the varying prevalence of “critical” and “non-critical” security debt among applications written in different languages. Critical security debt is defined for this report as high-severity flaws that remain unfixed for longer than a year. If exploited, these flaws would put the integrity and availability of organizations at serious risk.

The research found that while most security debt exists in first-party code written by in-house developers, the most critical security debt resides in third-party code (e.g., open-source software imported into the codebase). For example, 80 percent of critical debt in Java apps, and 63 percent in JavaScript apps, is in third-party code. The report also found about 51 percent of critical flaws in Java apps turn into security debt, while only about 45 percent of low to medium flaws progress into security debt.

Eng said, “With the overflowing volume of security flaws, developers are not prioritizing those that present the most risk. While focusing on non-critical flaws may result in some quick fixes, developers should use their limited capacity to work on fixing critical flaws with the highest potential impact on security.”

Putting Visibility and Prioritization First: Universal Connector & Application Security Heatmap

Building on Veracode’s acquisition of Longbow Security in April this year, and the introduction of Longbow’s Repo Risk Visibility and Analysis capability in May, Universal Connector and Application Security Heatmap are designed with developers’ time in mind. The capabilities provide operational oversight to help developers and security teams quickly identify and prioritize the most important fixes for growing security debt across their applications.

Universal Connector allows organizations to quickly access disparate source data they otherwise couldn’t bring into the Longbow platform, meaning they don’t have to wait for a tool-specific connector. The Application Security Heatmap maps the application back to the owner and shows a 90-day risk trend, as well as enabling customization of the risk threshold to meet organizational policy. Application security teams and developers can analyze each application, view the distribution of risk, and implement recommendations for the Best Next Action™ to remediate that risk.

“As organizations seek to find and fix mounting critical security debt, the need for risk-focused visibility and prioritization is clear,” said Derek Maki, Vice President of Product Management at Veracode. “The new capabilities in the Longbow platform provide our customers with a deeper understanding of an organization’s riskiest applications, plus the unique ability to identify the top five most impactful solutions for improvement.”

Enhanced by the Longbow acquisition, Veracode closes the gap between development and security teams, delivering visibility from code repositories to cloud assets and runtime. Longbow also identifies infrastructure-as-code and misconfiguration risk for cloud assets originating from repositories.

The Longbow Universal Connector and Application Security Heatmap are available immediately. For more information, please visit the website or watch the interview with Brian Roche, Veracode Chief Executive Officer, and Derek Maki.

The full State of Software Security 2024 Language Snapshot is available on the Veracode website.

Visitors to the Black Hat USA Conference, August 3-8, 2024, can learn more about Veracode’s platform and these new features by visiting Veracode’s booth #2536 for a demo.

About the State of Software Security Report

The Veracode State of Software Security 2024 report analyzed data from large and small companies, commercial software suppliers, software outsourcers, and open-source projects. The research draws from more than a million (1,007,133) applications across all scan types, 1,553,022 dynamic analysis scans, and 11,429,365 static analysis scans. All those scans produced 96 million raw static findings, 4 million raw dynamic findings, and 12.2 million raw software composition analysis findings.

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale. Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240801020287/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye